276 related articles for article (PubMed ID: 2698794)
1. Beta-lactamase stability and antibacterial activity of cefpirome alone and in combination with other antibiotics.
Bakhtiar M; Selwyn S
Drugs Exp Clin Res; 1989; 15(10):477-82. PubMed ID: 2698794
[TBL] [Abstract][Full Text] [Related]
2. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
Inoue K; Inoue E; Mitsuhashi S
Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
[TBL] [Abstract][Full Text] [Related]
4. [Activity of cefpirome against bacteria isolated from hospitalized patients].
Fernández A; Herran I; de Mier C; Marcenac FM
Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748
[TBL] [Abstract][Full Text] [Related]
5. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activity of the new semisynthetic cephalosporin cefpirome.
Mitsukude M; Inoue M; Mitsuhashi S
Arzneimittelforschung; 1989 Jan; 39(1):26-30. PubMed ID: 2785801
[TBL] [Abstract][Full Text] [Related]
7. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
8. In-vitro antibacterial activity of DQ-2556 and its stability to various beta-lactamases.
Fujimoto T; Watanabe M; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Sep; 26(3):329-41. PubMed ID: 2228824
[TBL] [Abstract][Full Text] [Related]
9. The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria.
Zhang YL; Li JT
Int J Antimicrob Agents; 2001 Feb; 17(2):143-6. PubMed ID: 11165119
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of LB10522, a new catecholic cephalosporin.
Kim MY; Oh JI; Paek KS; Kim YZ; Kim IC; Kwak JH
Antimicrob Agents Chemother; 1996 Aug; 40(8):1825-31. PubMed ID: 8843288
[TBL] [Abstract][Full Text] [Related]
12. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.
Neu HC; Chin NX; Labthavikul P
Infection; 1985; 13(3):146-55. PubMed ID: 3928497
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance.
Murray PR; Niles AC
Diagn Microbiol Infect Dis; 1986 Jan; 4(1):53-63. PubMed ID: 3632921
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM
Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181
[TBL] [Abstract][Full Text] [Related]
16. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of a new cephalosporin ME-1206 compared with other agents.
Chin NX; Zhang YX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(5):417-24. PubMed ID: 1797456
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum.
Song HK; Oh JI; Kim MY; Kim YZ; Kim IC; Kwak JH
J Antimicrob Chemother; 1996 Apr; 37(4):711-26. PubMed ID: 8722537
[TBL] [Abstract][Full Text] [Related]
20. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
